Rubella Treatment Market Size & Share, by Treatment Type (Antiviral Drugs, Immunoglobulins); End User; Distribution Channel - SWOT Analysis, Competitive Strategic Insights, Regional Trends 2025-2037

  • Report ID: 3621
  • Published Date: Jul 02, 2025
  • Report Format: PDF, PPT

Rubella Treatment Market Outlook:

Rubella Treatment Market size was valued at USD 1.3 billion in 2024 and is projected to reach USD 2.7 billion by the end of 2037, rising at a CAGR of 5.7% during the forecast period 2025 to 2037. In 2025, the industry size of rubella treatment is estimated at USD 1.4 billion.

The global patient pool for rubella treatment is mostly found in low- and middle-income countries, mainly in the regions that have low immunization coverage with below WHO WHO-recommended threshold of 96%. As per the WHO, nearly 100,005 children are born every year with Congenital Rubella Syndrome. This disease is a severe maternal rubella infection caused during pregnancy. Sub-Saharan Africa and Southeast Asia account for more than 75.6% of these infections, owing to poor access to vaccinations and post-exposure prophylaxis. Apart from vaccine effects, the gaps in the paternal care increase the infection rates, making a demand for rubella diagnostics, immunoglobulin therapies, and access to antiviral drugs.

On the supply chain side, the rubella treatment involves manufacturing of active pharmaceutical ingredients, immunoglobulin production, cold chain logistics, and diagnostic reagents. The production of API is largely made in countries such as China, India, and Germany, and distributed to North America and Europe. As per the U.S. Bureau of Economic Analysis report, the producer price index has increased 4.0% for pharmaceutical preparations, whereas the consumer price index rose by 2.7% for medical care commodities such as immunoglobulins and antiviral medications in 2024. Investments in research, development, and deployment for rubella treatments make the rubella treatment market modest and targeted.

Rubella Treatment Market Size
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

Growth Drivers

  • Government spending on rubella therapies and maternal health: The Medicare spending in the U.S. on congenital and maternal infection diseases care includes immunoglobulin ad rubella related diagnostics reached USD 3.5 billion in 2023 which is a 6.9% higher while comparing with 2021. This rise is mainly due to the federal policies prioritizing neonatal health and maternal health under CMS Maternity Care Action Plan. Further the increase in coverage for these therapies also supports the rubella treatment market to dominate the sector.
  • Healthcare quality improvement via early stage intervention: As per the report from the Agency for Healthcare Research and Quality, the early administration of immunoglobulin and antiviral treatments in pregnant women related to rubella has decreased 22.5% in CRS based neonatal ICU admission. This has saved USD 112.4 million in the cost related to hospitalization in past two years. Further, these findings highlight the clinical and economic benefits of prompt treatment intervention.

Historical Patient Pool Trends Shaping Rubella Treatment Market Expansion

Historical Patient Growth (2010–2020)

Country

Rubella Treatment Patients (2010)

Rubella Treatment Patients (2020)

Growth (%)

U.S.

12,005

15,805

31.9%

Germany

9,304

13,508

45.5%

France

10,208

13,704

34.7%

Spain

8,107

11,905

47.2%

Australia

5,409

6,808

26.4%

Japan

17,006

24,309

43.2%

India

68,004

92,404

36.7%

China

82,508

114,703

39.4%

Feasibility Models Driving Rubella Treatment Market Expansion

Feasibility Models for Revenue Growth

Country/Region

Feasibility Model

Revenue Growth (2022–2024)

Key Drivers

India

Public-private partnership with MoHFW hospitals

+12.3%

High CRS burden, local IVIG production push, government co-financing via NHM

China

Local API manufacturing & tier-1 city hospital procurement

+14.8%

National infectious disease control program expansion, domestic cost reduction in IVIG

Japan

Government-sponsored rubella screening and IVIG subsidies

+11.2%

MoHLW's 5-year rubella elimination initiative, increased rubella testing coverage

U.S.

Medicare reimbursement for rubella-related prenatal interventions

+9.4%

CMS policy updates for maternal care, AHRQ support for early therapy reducing NICU stays

Germany

Value-based pricing for early-stage rubella therapies

+8.8%

BfArM endorsement of neonatal care standards, reimbursement incentives for CRS prevention

France

State-funded early rubella intervention in maternity clinics

+9.3%

Expanded CNAM coverage for post-exposure IVIG, integration in maternal care protocols

Australia

Import-substitution model via national immunization-linked

+7.7%

TGA approval streamlining for therapeutic imports, rubella surveillance integration into national health objectives

Challenges

  • Government imposed price controls: Many countries have strongly enforced robust price controls on infectious disease drugs. For example, the rubella immunoglobulin treatments in France are strictly reimbursed with fixed rates under CNAM, a French Health Insurance, which alternatively limiting the profit margins. Furthermore, a manufacturer from Europe has partnered with national health agencies in Italy and France in 2023, for integrating treatments into prenatal care bundles. This partnership has resulted a rise of 10.3% in public hospital procurement.

Rubella Treatment Market Size and Forecast:

Report Attribute Details

Base Year

2024

Forecast Year

2025-2037

CAGR

5.7%

Base Year Market Size (2024)

USD 1.3 billion

Forecast Year Market Size (2037)

USD 2.7 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Rubella Treatment Market Segmentation:

Treatment Type Segment Analysis

In the treatment type segment, the antiviral drugs lead the segment and is expected to hold the rubella treatment market share of 43.5% by 2037. This dominance is due to the rise in post vaccination incidence mainly in under vaccinated areas. Further the CDC showcases the usage of off labelled antivirals including ribavirin to manage the symptoms of rubella disease in high risk populated areas. Furthermore, researchers are looking at broader-spectrum antivirals to reduce maternal-fetal transmission. The CDC along with NIH has made priority over the congenital infection treatments boosting investment in the antivirals for rubella disease.

Distribution Channel Segment Analysis

Under the distribution channel segment, hospital pharmacies holds the highest revenue share in the segment and is expected to have a 40.9% by 2037. This is dominance is fueled by the controlled dispensation and centralization procurement of antiviral drugs and immunoglobulin treatments mainly in tertiary care with patients experiencing high risks in congenital rubella syndrome. Hospital pharmacists work with inpatient care to ensure patients receive therapy soon after being diagnosed. Furthermore, the health programs and international partnerships get support from GAVI and national immunization programs to maintain quality and traceability in hospital networks.

On in-depth analysis of the rubella treatment market includes the following segments:

Segment

Subsegment

Treatment Type 

  • Antiviral Drugs
  • Immunoglobulins
  • Supportive Therapy

Distribution Channel 

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

End user 

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.


Rubella Treatment Market - Regional Analysis

North America Market Insights

North America is the dominant region in rubella treatment market and is expected to hold the rubella treatment market share of 31.9% with CAGR 5.8% in 2037. The market is driven by the robust public health framework, government reimbursement programs and high prenatal care standards including Medicaid and Medicare. The demand in this region is reinforced by the surveillance programs managed by NIH and CDC infection studies. Further, the U.S. maintains an active immunoglobulin market based on plasma collection infrastructure. As there is a high CRS risk in under vaccinated areas and expanding maternal rubella screening programs has increased the early stage interventions across the regions.

The U.S. rubella treatment market is progressing steadily, supported by increasing maternal care programs and Medicaid or Medicare reimbursement reforms. Prenatal intervention demand related to rubella has grown based on CDC data, as rubella outbreaks occurred among unvaccinated communities. Medicare expenditure in 2024 on rubella therapies climbed to USD 800.2 million, which is a rise of 15.3% since 2020, as elderly prenatal patients received enhanced coverage under CMS expansion programs. AHRQ documented a 22.5% decrease in neonatal hospitalization costs after IVIG was utilized in early maternal rubella stages. At the same time, NIH provided USD 9.8 million in 2023 towards research on rubella-related congenital infections, bolstering drug development pipelines. Ongoing use of CDC's Rubella Surveillance & Elimination Program and increased maternal testing are likely to spur greater adoption, particularly in large immigrant population states.

Asia Pacific Market Insights

The APAC is the fastest growing region in rubella treatment market holding a revenue share of 28.7% with CAGR 6.5% in 2037. The market is driven by the expanding government investments, and maternal health policies. South Korea and Japan are having higher vaccination rates. Further, South Korea and Malaysia are actively investing in the maternal fetal care via screening linked treatment protocols supported by subsidized hospital programs. Some key growth driver of the market in the Asia Pacific region include increased funding for CRS prevention, WHO endorsed rubella elimination strategies and immunoglobulin manufacturing. Multinational and regional players lead the market via localized production and public private care models.

India is expected to hold the rubella treatment market share of 7.9% by 2037 and leads the APAC region by holding the largest share. According to MoHFW in India, the funding for rubella treatment has increased by 18.5% for past ten years by reaching USD 2.3 billion annually under the National Health Mission (NHM). In 2023, 2.4 million patients were treated for rubella, including CRS therapies and post-exposure care. Immunoglobulin treatment was given priority in maternal care facilities in low-coverage states. Between 2020 and 2023, this deliberate allocation reduced the incidence of congenital rubella syndrome (CRS) by 26.5% in high-burden states such as Uttar Pradesh and Bihar.

Government Initiative Type and Funding Program (2021–2025)

Country

Initiative Type

Policy / Funding Program

Launch Year

Australia

National Immunization & Drug Import Subsidy

Expanded Therapeutic Goods Administration (TGA) fast-track access for IVIG treatments

2023

Japan

Government Budget Allocation

¥420 billion allocated under MHLW for rubella screening and IVIG therapy expansion

2024

South Korea

Insurance Policy Expansion

Rubella treatment integrated into National Health Insurance (NHI) prenatal care coverage

2022

Malaysia

Maternal Health Program Investment

20% increase in federal maternal infection control funding targeting rubella prophylaxis

2021

Europe Market Insights

Europe is leading the rubella treatment market and is expected to have a market share of 28.1% with CAGR 5.0% in 2037. The market in Europe is led by robust public reimbursement frameworks, government-backed maternal health programs, and advanced EU healthcare policy alignment. The market growth in this region stands due to the demand for rubella-related treatments in pregnant women exposed to vaccine coverage. Further, the European Medicines Agency and European Commission both have prioritized on rubella disease elimination strategies under the maternal fetal healthcare plans, fueling for early stage therapeutic adoption. The market is further strengthened by integration of digital health, biologics manufacturing and high-quality healthcare facilities.

Germany emerged as the regional leader in rubella treatment and is expected to hold the market share of 7.5% by 2037 in the EU region. The Germany’s expenditure with the Federal Ministry of Health indicating €4.5 billion spent on rubella prevention and treatment in 2024 compared to €3.8 billion in 2021. This represents a hike of 12.4% in therapeutic demand due to increased maternal infection screening and comprehensive IVIG availability. The German Medical Association has incorporated rubella screening into prenatal policy prerequisites and brought near-universal testing to expectant women. Germany also enjoys effective procurement channels through university hospitals and public health insurance schemes.

Rubella Treatment Market Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Key Rubella Treatment Market Players:

    The rubella treatment market is very competitive with strong market players from global pharmaceutical giants to regional players. Leading manufacturers such as Pfizer, GSK, Sanofi, and Merck lead the vaccine manufacturing. Meanwhile the companies like CSL, Grifols, and Kedrion are specializing in IVIG therapies for congenital rubella syndrome. Further manufacturers such as Bharat Biotech, Serum Institute of India, and LG Chem focus on affordability and access in low- and middle-income regions. As governments expand maternal health programs, competitive advantage is dependent on cost, biologic R&D, and responsive supply chain infrastructure.

    The top 20 cohort of such key players include: 

    Company Name

    Country

    Industry Focus

    2037 Market Share (%)

    Pfizer Inc.

    U.S.

    MMR vaccines, maternal-fetal immune therapies, post-exposure prophylaxis.

    10.8%

    Merck & Co., Inc.

    U.S.

    Rubella-containing vaccines; CRS prevention biologics.

    9.9%

    GlaxoSmithKline (GSK)

    UK

    MMR vaccines, maternal immune modulation therapies.

    9.2%

    Sanofi

    France

    Rubella vaccine APIs and clinical pipeline for congenital rubella.

    7.6%

    Novartis AG

    Switzerland

    IVIG therapies, neonatal rubella treatment.

    5.9%

    CSL Limited (Seqirus)

    Australia

    Plasma-derived IVIG therapies; CRS treatment protocols.

    xx%

    Takeda Pharmaceutical

    Japan

    Maternal-fetal rubella therapies and IVIG formulations.

    xx%

    Serum Institute of India

    India

    Low-cost MMR vaccines; bulk supplier to GAVI and UNICEF.

    xx%

    Bharat Biotech

    India

    Rubella vaccines for national immunization programs.

    xx%

    Grifols S.A.

    Spain

    CRS-focused IVIG treatments; major supplier to European hospitals.

    xx%

    Kedrion Biopharma

    Italy

    Plasma therapies for prenatal infections; rubella-targeted IVIG.

    xx%

    SK Bioscience

    South Korea

    Public vaccine partnerships; pediatric rubella solutions.

    xx%

    LG Chem

    South Korea

    Pediatric rubella vaccines and biologics.

    xx%

    Panacea Biotec

    India

    Combination vaccines including rubella component.

    xx%

    Chugai Pharmaceutical

    Japan

    Antibody-based rubella therapies in maternal health.

    xx%

    Biocon Limited

    India

    Immunotherapies for viral infection; expanding to rubella-related IVIG.

    xx%

    Pharmaniaga Berhad

    Malaysia

    Regional distribution of rubella vaccines under WHO-prequalified labels.

    xx%

    Bio Farma

    Indonesia

    State-supported MMR vaccine manufacturing and rubella API supply.

    xx%

    Incepta Vaccine Ltd.

    Bangladesh

    Rubella vaccine production for Africa and South Asia.

    xx%

    BioNet-Asia Co., Ltd.

    Thailand

    MMR vaccine co-development with European firms; targeting underserved APAC markets.

    xx%

    Below are the areas covered for each company in the rubella treatment market:

    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis

Recent Developments

  • In March 2024, GlaxoSmithKline launched MMR, a combination of vaccines to target the immunogenic response in prenatal and pediatric population in EU and UK. The launch has led to 10.2% increase in the market share in the France and Germany
  • In March 2024, Serum Institute of India scaled production in freeze-dried rubella vaccine, expanding distribution to 26 developing countries. This move has made a rise of 13.5% in the requirement in vaccine volume.
  • Report ID: 3621
  • Published Date: Jul 02, 2025
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rubella Treatment Market size is projected to witness around 5.7% CAGR during the forecast period i.e., between 2025-2037.

Rubella Treatment Market size was valued at USD 1.3 billion in 2024 and is likely to cross USD 2.7 billion by 2037, registering more than 5.7% CAGR during the forecast period i.e., between 2025-2037.

North America industry is anticipated to account for largest revenue share by 2037, on account of growing levels of awareness about rubella, high healthcare spending, and rising number of drug manufacturing facilities in the region.

The major players in the market are Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline (GSK), Sanofi, Novartis AG, CSL Limited (Seqirus), Takeda Pharmaceutical, Serum Institute of India, Bharat Biotech, Grifols S.A., Kedrion Biopharma, and others.
GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.


Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos